Development of potential anticancer agents that target the telomere sequence

The immortality of cancer cells is due to the relatively high concentration of telomerase enzyme that maintains the telomere sequence during cell division. Human telomeric DNA consists of repeats of the sequence d(5′-TTAGGG-3′). Deoxyribonucleic guanidine (DNG) is a DNA analog in which positively charged guanidine [–NH–C(NH2+)–NH–] replaces the negatively charged phosphodiester of DNA. The synthesized DNG hexamer AgAgTgCgCpC and dodecamer AgAgTgCgCgCAgAgTgCgCpC are complementary to the non-coding telomere sequence d(5′-TTAGGG-3′). We have found that binding of the complementary DNG hexamer to the telomere is favored over that of DNA telomere by 102.5-fold and binding the dodecamer with 2-mismatched DNA is favored by 105-fold. We have shown that DNG binding to RNA is favored over binding to DNA. A complementary complex of DNG with RNA at the active site of telomerase enzyme would be very stable.

Oligonucleotides containing positively charged ribonucleic guanidine linkages (DNG I, II) have been synthesized to develop anticancer agents targeting telomere. Binding properties of DNG I, II are presented.Figure optionsDownload as PowerPoint slide